Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

Geraldine O’Sullivan Coyne, Lihua Wang, Jennifer Zlott, Lamin Juwara, Joseph M. Covey, Jan H. Beumer, Mihaela Cristea, Edward M. Newman, S. Koehler, Jorge J. Nieva, Agustin A. García, David R. Gandara, Brandon Miller, Sonny Khin, Sarah Miller, Seth M. Steinberg, Larry Rubinstein, Ralph E. Parchment, Robert J. Kinders, Richard Piekarz, Shivaani Kummar, Alice P. Chen, James H. DoroshowCancer 2020 · DOI

Abstract

Further study of FdCyd + THU is potentially warranted in urothelial carcinoma but not NSCLC or breast or H&N cancer. Increase in the proportion of p16-expressing cytokeratin-positive CTCs is a pharmacodynamic marker of FdCyd target engagement.

Introduction

Epigenetic silencing of tumor suppressor genes via DNA methylation is a hallmark of cancer progression. While DNA methyltransferase (DNMT) inhibitors like decitabine are approved for hematologic malignancies, their instability and toxicity have limited their utility in solid tumors. This study investigates 5-fluoro-2′-deoxycytidine (FdCyd), a more stable analog, administered with tetrahydrouridine (THU) to prevent metabolic degradation. A primary objective was to validate a novel "liquid biopsy" assay using circulating tumor cells (CTCs) to monitor real-time target engagement—specifically the reactivation of the silenced p16/INK4A gene.

Methods

This Phase 2 trial enrolled 95 patients across four strata: breast, head and neck (H&N), non-small cell lung (NSCLC), and urothelial cancer. Patients received IV FdCyd (100 mg/m²) and THU (350 mg/m²) for two weeks of a 28-day cycle.

To assess pharmacodynamics, the researchers modified the FDA-cleared CellSearch® system, adding a fifth fluorescence channel to detect p16 protein expression in CTCs. The assay distinguished between "classic" epithelial (Cytokeratin-positive) and mesenchymal-like (Vimentin-positive) CTCs.

Results

Clinical Efficacy and Survival

Clinical response was modest across most cohorts. However, the urothelial stratum showed a 4-month progression-free survival (PFS) rate of 42%, meeting the study's predefined threshold for further investigation. In contrast, breast, H&N, and NSCLC cohorts did not meet efficacy benchmarks.

Progression-free survival (PFS) from start of therapy across the four cancer cohorts. The urothelial cohort (red) showed the most favorable survival profile.

Biomarker Validation and Target Engagement

The 5-channel CTC assay successfully demonstrated drug target engagement. Significant increases in p16-expressing CTCs were observed in 69% of evaluable patients, often as early as day 12 of the first treatment cycle.

Treatment cycles and p16 biomarker response in the urothelial cohort. Blue circles indicate an increase in the proportion of p16+ CK+ CTCs, demonstrating successful gene reactivation.

Interestingly, mesenchymal-like (Vimentin-positive) CTCs were significantly more abundant than epithelial ones but appeared more resistant to p16 reactivation, suggesting these aggressive cell populations may require different therapeutic strategies.

Discussion

While the overall objective response rate was low, this study provides a critical "proof of concept" for using CTCs as a non-invasive pharmacodynamic marker for epigenetic therapies. The sensitivity observed in urothelial cancer suggests a potential role for FdCyd+THU in this population, perhaps as a priming agent for immunotherapy.

Major limitations included the high administration burden (ten 3-hour infusions per month) and the small number of patients with sufficient CTC counts for biomarker analysis. Future efforts are focusing on an oral formulation of FdCyd+THU to improve patient feasibility and enable broader clinical application.

Summary updated

Abstract

Further study of FdCyd + THU is potentially warranted in urothelial carcinoma but not NSCLC or breast or H&N cancer. Increase in the proportion of p16-expressing cytokeratin-positive CTCs is a pharmacodynamic marker of FdCyd target engagement.
BibTeX
@inproceedings{coyne2020intravenous,
  author = {Geraldine O’Sullivan Coyne and Lihua Wang and Jennifer Zlott and Lamin Juwara and Joseph M. Covey and Jan H. Beumer and Mihaela Cristea and Edward M. Newman and S. Koehler and Jorge J. Nieva and Agustin A. García and David R. Gandara and Brandon Miller and Sonny Khin and Sarah Miller and Seth M. Steinberg and Larry Rubinstein and Ralph E. Parchment and Robert J. Kinders and Richard Piekarz and Shivaani Kummar and Alice P. Chen and James H. Doroshow},
  title = {{Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors}},
  booktitle = {Cancer},
  year = {2020},
  doi = {10.1007/s00280-020-04073-5},
}
Figure